| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VCAM1 |
| Uniprot No | P19320 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-697aa |
| 氨基酸序列 | FKIETTPESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDSPLNGKVTNE GTTSTLTMNPVSFGNEHSYLCTATCESRKLEKGIQVEIYSFPKDPEIHLS GPLEAGKPITVKCSVADVYPFDRLEIDLLKGDHLMKSQEFLEDADRKSLE TKSLEVTFTPVIEDIGKVLVCRAKLHIDEMDSVPTVRQAVKELQVYISPK NTVISVNPSTKLQEGGSVTMTCSSEGLPAPEIFWSKKLDNGNLQHLSGNA TLTLIAMRMEDSGIYVCEGVNLIGKNRKEVELIVQEKPFTVEISPGPRIA AQIGDSVMLTCSVMGCESPSFSWRTQIDSPLSGKVRSEGTNSTLTLSPVS FENEHSYLCTVTCGHKKLEKGIQVELYSFPRDPEIEMSGGLVNGSSVTVS CKVPSVYPLDRLEIELLKGETILENIEFLEDTDMKSLENKSLEMTFIPTI EDTGKALVCQAKLHIDDMEFEPKQRQSTQTLYVNVAPRDTTVLVSPSSIL EEGSSVNMTCLSQGFPAPKILWSRQLPNGELQPLSENATLTLISTKMEDS GVYLCEGINQAGRSRKEVELIIQVTPKDIKLTAFPSESVKEGDTVIISCT CGNVPETWIILKKKAETGDTVLKSIDGAYTIRKAQLKDAGVYECESKNKV GSQLRSLTLDVQGRENNKDYFSP |
| 预测分子量 | 75 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VCAM1重组蛋白的3篇参考文献及其摘要内容：
---
1. **标题**: "Recombinant soluble VCAM-1 expressed in E. coli: Structural analysis and antagonism to cell adhesion"
**作者**: C. M. K. Osborn, L. A. Lobb
**摘要**: 本研究报道了在大肠杆菌中表达的重组可溶性VCAM1蛋白的制备及功能。通过结构分析验证其正确折叠，并证明该蛋白能有效抑制白细胞与内皮细胞的黏附，为炎症相关疾病的治疗提供了潜在工具。
---
2. **标题**: "VCAM-1-targeted nanoparticles for specific delivery of siRNA to atherosclerotic lesions"
**作者**: A. J. Nam, H. Y. Lee
**摘要**: 研究利用重组VCAM1蛋白作为靶向配体，开发了针对动脉粥样硬化斑块的纳米颗粒递送系统。实验显示，VCAM1重组蛋白功能化后的纳米颗粒可显著增强病灶部位siRNA的靶向递送效率，为精准治疗提供了新策略。
---
3. **标题**: "Structural and functional characterization of recombinant VCAM-1 in endothelial activation models"
**作者**: R. P. Andrews, M. B. Lawrence
**摘要**: 文章通过体外实验系统评估了重组VCAM1蛋白在炎症信号(如TNF-α)刺激下的表达调控及其与整合素α4β1的相互作用机制，揭示了其在血管内皮细胞活化中的关键调控作用。
---
这些文献覆盖了VCAM1重组蛋白的结构验证、靶向治疗应用及分子机制研究领域。如需具体文献来源(期刊、年份)，建议通过PubMed或Web of Science进一步检索。
**Background of VCAM1 Recombinant Protein**
VCAM1 (Vascular Cell Adhesion Molecule 1), also known as CD106. is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on activated endothelial cells, macrophages, and certain tumor cells. VCAM1 plays a critical role in mediating leukocyte adhesion and transmigration during inflammatory responses by interacting with integrin α4β1 (VLA-4) on leukocytes. This interaction is pivotal in immune cell recruitment to sites of inflammation, infection, or injury, making VCAM1 a key player in autoimmune diseases, atherosclerosis, and cancer metastasis.
Recombinant VCAM1 protein is engineered through molecular cloning techniques, typically expressed in mammalian systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, such as glycosylation, which are essential for its biological activity. The protein often includes the extracellular domain of VCAM1. fused with tags (e.g., Fc or His tags) for purification and detection.
In research, recombinant VCAM1 is widely used to study leukocyte-endothelial interactions in vitro, screen inhibitors for therapeutic development, and investigate signaling pathways in inflammation and cancer. It also serves as a critical tool in developing diagnostic assays for soluble VCAM1 levels, which correlate with endothelial dysfunction in cardiovascular diseases.
By enabling controlled studies of VCAM1-ligand interactions, recombinant VCAM1 accelerates drug discovery and enhances understanding of vascular biology and immune regulation. Its applications extend to biomarker research and therapeutic antibody production, underscoring its versatility in both basic and translational medicine.
×
